// App-Quantinova.ai

: Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.

Researchers

Presenter

  • Aiwu Ruth He

Principal Investigators

  • Benjamin R. Tan

  • Thatthan Suksombooncharoen

  • Hidenori Takahashi

  • Ming-Huang Chen

  • Vikas S Ostwal

  • Sang Cheul Oh

  • Emel Sezer

  • Piotr Potemski

  • Kun-Ming Rau

  • Ekaphop Sirachainan

  • Junhe Li

  • Jean-Frédéric Blanc

  • Gordon Cohen

  • Magdalena Żotkiewicz

  • Nana Rokutanda

  • Do-Youn Oh

Medical Centers

  • Department of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, China

  • Department of Hematology-Oncology, E-Da Cancer Hospital and College of Medicine, I-Shou University, Kaohsiung, Taiwan

  • Division of Hematology-Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

  • Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

  • Washington University School of Medicine, St. Louis, MO

  • Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

  • Department of Medical & Pediatric Oncology, Tata Memorial Hospital, Mumbai, India

  • Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland

  • Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea, Republic of (South)

  • Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

  • Department of Hepato-gastroenterology and Digestive Oncology, Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France

  • Oncology Biometrics, Late Oncology Statistics, AstraZeneca, Warsaw, Poland

  • Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg, MD

  • Department of Gastroenterological Surgery, Osaka International Cancer Institite, Osaka, Japan

  • Department of Neurology, Mersin University Medical Faculty, Mersin

  • Division of Hematology/Oncology, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC

Locations

  • Republic of South Korea

  • United States

  • Poland

  • Turkey

  • India

  • China

  • Thailand

  • Taiwan

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Extrahepatic cholangiocarcinoma

  • Gallbladder cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Durvalumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03875235

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved